Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib

News
Video

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
A panel of 3 experts on CML
Related Content
The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

FDA Grants Priority Review to Revumenib in R/R NPM1-Mutant AML

Russ Conroy
June 25th 2025
Article

The FDA has set a Prescription Drug User Fee Act date of October 25, 2025, for approving revumenib in this acute myeloid leukemia population.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

Jax DiEugenio
June 17th 2025
Article

Single-agent olutasidenib maintenance demonstrated clinically meaningful activity in patients with IDH1-mutated acute myeloid leukemia.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML

Gina Mauro
June 15th 2025
Article

Data from ASCERTAIN-V may support venetoclax plus decitabine/cedazuridine as a new standard of care in those with AML ineligible to receive chemotherapy.

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Ariana Pelosci
June 14th 2025
Article

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.